Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Zhitong Finance APP has learned that long-term data from two phase 3 clinical trials by Johnson & Johnson (JNJ.US) show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved clinical remission rates of up to 94% within three years.

According to the report, participants in the GALAXI 2 and GALAXI 3 trials first received Tremfya induction therapy, followed by maintenance therapy of either 100 mg every eight weeks or 200 mg every four weeks. The remission rate was 94% in the eight-week regimen group and 91% in the four-week regimen group.

In addition, 52% of patients in the eight-week regimen group achieved endoscopic remission, compared to 61% in the four-week regimen group.

Meanwhile, 88% of patients in both groups achieved steroid-free clinical remission for 90 days.

Furthermore, Johnson & Johnson stated that results from the phase 3 FUZION study showed that Tremfya achieved sustained fistula remission in certain subgroups of Crohn's disease patients.

Overall, 28% of patients in the eight-week (q8w) regimen group and 27% in the four-week (q4w) regimen group reached the composite endpoint of fistula comprehensive remission at Week 24, compared to 10% in the placebo group.

However, among patients with higher baseline luminal disease activity, the remission rates were 30% for the q8w group and 21% for the q4w group, while the placebo group achieved 0%.

In patients previously treated with biologics, and in patients with or without rectal inflammation at baseline, those treated with Tremfya also had significantly better fistula remission outcomes compared to the placebo group.